Bank of New York Mellon’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-12,636
Closed -$1.5M 4562
2021
Q1
$1.5M Buy
12,636
+5,132
+68% +$607K ﹤0.01% 3094
2020
Q4
$886K Sell
7,504
-9,853
-57% -$1.14M ﹤0.01% 3318
2020
Q3
$1.93M Buy
17,357
+423
+2% +$45.4K ﹤0.01% 2691
2020
Q2
$1.73M Buy
16,934
+2,266
+15% +$242K ﹤0.01% 2764
2020
Q1
$1.58M Buy
14,668
+6,908
+89% +$794K ﹤0.01% 2669
2019
Q4
$903K Sell
7,760
-9,060
-54% -$1.05M ﹤0.01% 3298
2019
Q3
$1.93M Sell
16,820
-456
-3% -$45.3K ﹤0.01% 2773
2019
Q2
$1.65M Buy
17,276
+357
+2% +$33.6K ﹤0.01% 2907
2019
Q1
$1.54M Sell
16,919
-10,614
-39% -$869K ﹤0.01% 2918
2018
Q4
$2.09M Sell
27,533
-199,253
-88% -$14.7M ﹤0.01% 2701
2018
Q3
$18.1M Sell
226,786
-56,849
-20% -$5.3M ﹤0.01% 1689
2018
Q2
$28.2M Sell
283,635
-322,456
-53% -$27.9M 0.01% 1387
2018
Q1
$49.1M Sell
606,091
-198,404
-25% -$16M 0.01% 1018
2017
Q4
$63.4M Buy
804,495
+41,711
+5% +$3.47M 0.02% 854
2017
Q3
$70.4M Buy
762,784
+176,325
+30% +$16.9M 0.02% 776
2017
Q2
$66.3M Buy
586,459
+22,932
+4% +$2.56M 0.02% 795
2017
Q1
$56.4M Buy
563,527
+31,297
+6% +$3.34M 0.02% 882
2016
Q4
$57.2M Sell
532,230
-5,176
-1% -$605K 0.02% 848
2016
Q3
$66.9M Buy
537,406
+29,888
+6% +$3.53M 0.02% 719
2016
Q2
$54M Buy
507,518
+34,308
+7% +$3.98M 0.02% 814
2016
Q1
$54.2M Buy
473,210
+98,882
+26% +$11.6M 0.02% 823
2015
Q4
$53.3M Sell
374,328
-9,852
-3% -$1.14M 0.02% 816
2015
Q3
$34.5M Buy
384,180
+153,444
+67% +$16.2M 0.01% 1064
2015
Q2
$26.6M Buy
230,736
+188,940
+452% +$19.9M 0.01% 1275
2015
Q1
$3.99M Buy
41,796
+30,715
+277% +$2.3M ﹤0.01% 2438
2014
Q4
$745K Buy
+11,081
New +$687K ﹤0.01% 3460

Bank of New York Mellon's CBPO Position: Q2 2021 in Review

Bank of New York Mellon sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 12,636 shares — an estimated $1.5M sold.

Bank of New York Mellon first reported a position in CBPO in Q4 2014 and held it in 26 quarters. The position peaked at $70.4M in Q3 2017. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

  • Bank of New York Mellon reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
  • Bank of New York Mellon sold 12,636 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $1.5M.
  • Bank of New York Mellon first reported a position in China Biologic Products Holdings, Inc. in Q4 2014 and held it in 26 quarters.
  • Bank of New York Mellon's China Biologic Products Holdings, Inc. position peaked at $70.4M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on Bank of New York Mellon's 13F filing for Q2 2021, filed 11 Aug 2021.